BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common Stock

  BioMed Realty Trust Prices Public Offering Of 12,700,000 Shares Of Common

PR Newswire

SAN DIEGO, Feb. 13, 2013

SAN DIEGO, Feb. 13, 2013 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE: BMR)
today announced the pricing of its public offering of 12,700,000 shares of its
common stock at $20.50 per share. The offering is expected to close on or
about February 19, 2013. The gross proceeds from the offering will be
approximately $260.4 million. BioMed Realty expects to use the net proceeds
of the offering to fund a recently announced property acquisition, to fund a
portion of the redemption of all 7,920,000 outstanding shares of its 7.375%
Series A Cumulative Redeemable Preferred Stock, to repay a portion of the
outstanding indebtedness under its unsecured line of credit and for other
general corporate and working capital purposes. All of the shares are being
sold by the company.

BioMed Realty has also granted the underwriters a 30-day option to purchase up
to an additional 1,905,000 shares of its common stock. Morgan Stanley & Co.
LLC, Raymond James & Associates, Inc., UBS Securities LLC and Wells Fargo
Securities, LLC are the joint book-running managers for the offering.

The registration statement relating to these securities has become effective
by rule of the Securities and Exchange Commission. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy any of
the offered shares, nor shall there be any sale of such shares in any state or
other jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of
such state or other jurisdiction. The offering of BioMed Realty's common
stock will be made only by means of a prospectus and a related prospectus
supplement, copies of which may be obtained by contacting Morgan Stanley & Co.
LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New
York 10014, at 1-866-718-1649 or by email at;
Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg,
Florida 33716, by calling toll-free at 1-800-248-8863 or by email at; UBS Securities LLC, Attention: Prospectus
Department, 299 Park Avenue, New York, New York 10171, or toll-free at
1-888-827-7275; or Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 375 Park Avenue, New York, New York 10152, at 1-800-326-5897 or by
email at

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.1
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
Maryland, San Diego, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with downturns in foreign, domestic and local
economies, changes in interest rates and foreign currency exchange rates, and
volatility in the securities markets; ownership of properties outside of the
United States that subject the company to different and potentially greater
risks than those associated with the company's domestic operations; risks
associated with the company's investments in loans, including borrower
defaults and potential principal losses; potential liability for uninsured
losses and environmental contamination; risks associated with the company's
potential failure to qualify as a REIT under the Internal Revenue Code of
1986, as amended, and possible adverse changes in tax and environmental laws;
and risks associated with the company's dependence on key personnel whose
continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most recent annual
report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

SOURCE BioMed Realty Trust, Inc.

Contact: Rick Howe, Senior Director, Corporate Communications,
Press spacebar to pause and continue. Press esc to stop.